Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection

• DOI: 10.1128/aac.00007-19
• Publication Date: 2019-02-12T11:31:39Z
• Authors: Amit Kaushik; Nicole C. Ammerman; Sandeep Tyagi; Vikram Saini; Iwan Vervoort; Sophie Lachau-Durand; Eric Nuermberger; Koen Andries
• Keywords: Male; 0301 basic medicine; Mice, Inbred BALB C; Antitubercular Agents; Administration, Oral; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Injections, Intramuscular; 3. Good health; Disease Models, Animal; Mice; 03 medical and health sciences; Latent Tuberculosis; Animals; Experimental Therapeutics; Female; Diarylquinolines

The potent antituberculosis activity and long half-life of bedaquiline make it an attractive candidate for use in long-acting/extended-release formulations for the treatment of latent tuberculosis infection (LTBI). Our objective was to evaluate a long-acting injectable (LAI) bedaquiline formulation in a validated paucibacillary mouse model of LTBI.